Tharimmune (THAR) restores Nasdaq equity compliance as matter is closed

Rhea-AI Filing Summary

Tharimmune, Inc. reported that it has regained compliance with Nasdaq listing requirements related to stockholders’ equity. On September 5, 2025, the company received a letter from Nasdaq confirming that, based on a filing showing stockholders’ equity of $6,876,335 as of August 31, 2025, it meets Nasdaq Listing Rule 5550(b)(1). Nasdaq stated that the compliance matter is now closed, meaning Tharimmune’s common stock continues to qualify for listing on The Nasdaq Stock Market.

Positive

• Nasdaq equity compliance restored: Nasdaq confirmed Tharimmune meets Listing Rule 5550(b)(1) based on $6,876,335 of stockholders’ equity as of August 31, 2025, and closed the matter.

Negative

• None.

Insights

Equity & Listing Standards Analyst

Nasdaq confirms Tharimmune meets equity listing rule, closing the prior compliance issue.

Nasdaq’s letter confirms that Tharimmune now complies with Listing Rule 5550(b)(1), which requires a minimum level of stockholders’ equity for continued listing on the Nasdaq Capital Market. The confirmation is based on a filing showing stockholders’ equity of $6,876,335 as of August 31, 2025.

This resolution removes an overhang related to potential delisting tied to equity levels. Maintaining a Nasdaq listing can be important for trading liquidity and access to capital markets, although the filing does not discuss broader financial performance or future plans. Subsequent periodic reports will provide more detail on whether the company maintains equity at or above required thresholds.

false 0001861657 0001861657 2025-09-05 2025-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 5, 2025

THARIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41210		84-2642541
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

34 Shrewsbury Avenue, Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices, including zip code)

(732) 889-3111

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		THAR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 5, 2025, Tharimmune, Inc. (the “Company”) received a letter from Nasdaq stating that based on the Company’s Form 8-K filed on September 5, 2025 evidencing stockholders’ equity of $6,876,335 as of August 31, 2025, Nasdaq has determined that the Company complies with Listing Rule 5550(b)(1) and the matter is now closed.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 5, 2025	Tharimmune, Inc.
	/s/ Sireesh Appajosyula
	Sireesh Appajosyula
	Chief Executive Officer

-3-

FAQ

What did Tharimmune (THAR) announce in this 8-K filing?

Tharimmune reported that it received a letter from Nasdaq on September 5, 2025 confirming the company complies with Listing Rule 5550(b)(1), and that the related compliance matter is now closed.

How much stockholders’ equity did Tharimmune (THAR) report?

Tharimmune submitted a filing evidencing stockholders’ equity of $6,876,335 as of August 31, 2025, which Nasdaq used to determine compliance with its equity listing rule.

Which Nasdaq rule does Tharimmune now comply with?

Nasdaq determined that Tharimmune complies with Listing Rule 5550(b)(1), which concerns the minimum required level of stockholders’ equity for companies listed on the Nasdaq Capital Market.

What does it mean that the Nasdaq matter is now closed for Tharimmune?

Nasdaq stating the matter is now closed means the prior equity-related listing deficiency has been resolved, and Tharimmune’s common stock remains listed on The Nasdaq Stock Market under the symbol THAR.

Who signed the Tharimmune 8-K related to Nasdaq compliance?

The 8-K was signed on behalf of Tharimmune by Sireesh Appajosyula, who is identified as the company’s Chief Executive Officer.